These observations imply that PSM.7-LP diminished the activity of ERE73 (1 + 2)-ARF (−13) and ERE73 (3 + 4)-ARF (−13) through suppression of deregulated E2F activity in the cancer cell lines, supporting the notion that deregulated E2F activity confers high cancer cell specificity on the ERE73 (1 + 2)-ARF (−13) and ERE73 (3 + 4)-ARF (−13) constructs. Here, CDKN2A is linked to cancer.